Sanofi: will present its latest data at EADV

(CercleFinance.com) - Sanofi will present 39 abstracts on approved drugs and those in development at the 2024 medical meeting of the European Academy of Dermatology and Venereology (EADV), to be held 25-28 September in Amsterdam (Netherlands).


Presentations will include 21 abstracts for Dupixent (dupilumab) in partnership with Regeneron, highlighting the impact of targeting IL4 and IL13 in three chronic skin diseases, including disease remission and long-term data in children with moderate-to-severe atopic dermatitis (AD), and rapid results in adults with prurigo nodularis (PN).

In addition, data presentations from Sanofi's broad portfolio of immunological products include oral presentations of amlitelimab, an OX40-liganded monoclonal antibody, demonstrating safety and efficacy results in moderate-to-severe atopic dermatitis, as well as presentations of rilzabrutinib, a new oral BTK inhibitor, showing its impact on symptoms of atopic dermatitis and moderate-to-severe chronic spontaneous urticaria (CSU).

Sanofi said that its results at EADV underline the breadth of our diverse and innovative approach in inflammatory dermatological diseases, including Alzheimer's disease, rheumatoid arthritis and Duchenne ulcer. The Dupixent data demonstrate the potential benefit of important therapeutic objectives such as clinical remission, as well as rapid and sustained efficacy.


Copyright (c) 2024 CercleFinance.com. All rights reserved.